OWN - NLM
DA - 20170807
LR - 20170807
IS - 1532-6535 (Electronic)
IS - 0009-9236 (Linking)
VI - 102
IP - 3
DP - 2017 Sep
TI - Drugs and the Kidneys: Clinical Pharmacology Perspectives.
PG - 368-372
LID - 10.1002/cpt.775 [doi]
AB - The focus of this edition of Clinical Pharmacolgoy & Therapeutics (CPT) is on
drugs and renal function and will not include a detailed discussion of kidney
disease and its treatment. It is well recognized that drugs affect the kidneys in
different ways, while kidney disease impacts drug metabolism and response. It is
impossible to underestimate the value of the kidneys to man in health and
disease, from regulation of fluid and electrolyte balance to participating in
drug metabolism and transport. Additionally, the kidneys serve as targets for
drugs used to treat cardiovascular (CV) diseases including hypertension and heart
failure, metabolic diseases such as diabetes mellitus and obesity, chronic kidney
disease (CKD), as well as playing a role in the regulation of several hormones.
Kidney damage may be distinguished from changes in kidney function using
biomarkers, as discussed in some detail in this issue.
CI - (c) 2017 ASCPT.
FAU - Vincent, John
AU - Vincent J
AD - Pfizer Inc., New York, New York, USA.
LA - eng
PT - Editorial
PL - United States
TA - Clin Pharmacol Ther
JT - Clinical pharmacology and therapeutics
JID - 0372741
EDAT- 2017/08/08 06:00
MHDA- 2017/08/08 06:00
CRDT- 2017/08/08 06:00
PHST- 2017/06/19 [received]
PHST- 2017/06/19 [accepted]
AID - 10.1002/cpt.775 [doi]
PST - ppublish
SO - Clin Pharmacol Ther. 2017 Sep;102(3):368-372. doi: 10.1002/cpt.775.